Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Buy
71
ALC Quote, Financials, Valuation and Earnings
Last price:
$80.73
Seasonality move
:
5.78%
Day range:
$80.64 - $81.69
52-week range:
$71.55 - $99.20
Dividend yield:
0.42%
P/E ratio:
38.36x
P/S ratio:
3.94x
P/B ratio:
1.80x
Volume:
1.8M
Avg. volume:
2.1M
1-year change:
-7.59%
Market cap:
$39.7B
Revenue:
$9.9B
EPS (TTM):
$2.10
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ALC
Alcon AG
|
$2.6B | $0.77 | 8.47% | 39.48% | $94.15 |
|
ADCT
ADC Therapeutics SA
|
$16.8M | -- | 8.4% | -- | $8.00 |
|
BSX
Boston Scientific Corp.
|
$5B | $0.71 | 15.72% | 105.56% | $126.48 |
|
NVS
Novartis AG
|
$13.9B | $2.31 | 4.45% | 37.94% | $134.88 |
|
SOLV
Solventum Corp.
|
$2.1B | $1.43 | -5.45% | 768.77% | $84.36 |
|
STAA
STAAR Surgical Co.
|
$89.4M | $0.28 | 57.14% | 39.51% | $25.88 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ALC
Alcon AG
|
$80.73 | $94.15 | $39.7B | 38.36x | $0.34 | 0.42% | 3.94x |
|
ADCT
ADC Therapeutics SA
|
$3.29 | $8.00 | $407.6M | -- | $0.00 | 0% | 5.06x |
|
BSX
Boston Scientific Corp.
|
$97.52 | $126.48 | $144.6B | 52.16x | $0.00 | 0% | 7.52x |
|
NVS
Novartis AG
|
$132.16 | $134.88 | $253.6B | 18.02x | $3.99 | 3.02% | 4.78x |
|
SOLV
Solventum Corp.
|
$85.43 | $84.36 | $14.8B | 9.83x | $0.00 | 0% | 1.77x |
|
STAA
STAAR Surgical Co.
|
$25.38 | $25.88 | $1.3B | 49.73x | $0.00 | 0% | 5.47x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ALC
Alcon AG
|
19.18% | -0.654 | 14.32% | 1.14x |
|
ADCT
ADC Therapeutics SA
|
208.63% | 6.517 | 101.54% | 4.15x |
|
BSX
Boston Scientific Corp.
|
33.99% | 0.345 | 8.31% | 0.81x |
|
NVS
Novartis AG
|
41.94% | 0.086 | 12.99% | 0.58x |
|
SOLV
Solventum Corp.
|
50.75% | 0.962 | 40.57% | 0.94x |
|
STAA
STAAR Surgical Co.
|
9.96% | 0.980 | 2.95% | 4.10x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ALC
Alcon AG
|
$1.5B | $347M | 3.87% | 4.8% | 13.28% | $535M |
|
ADCT
ADC Therapeutics SA
|
$15.1M | -$30.6M | -148.42% | -- | -186.23% | -$31.7M |
|
BSX
Boston Scientific Corp.
|
$3.3B | $1B | 8.19% | 12.46% | 20.55% | $1.2B |
|
NVS
Novartis AG
|
$10.3B | $4.2B | 19.37% | 33.87% | 30.24% | $5.7B |
|
SOLV
Solventum Corp.
|
$1.1B | $171M | 13.6% | 42.2% | 8.16% | -$21M |
|
STAA
STAAR Surgical Co.
|
$76.6M | $44.5M | -23.38% | -25.83% | 46.96% | $1.8M |
Alcon AG vs. Competitors
-
Which has Higher Returns ALC or ADCT?
ADC Therapeutics SA has a net margin of 9.07% compared to Alcon AG's net margin of -249.38%. Alcon AG's return on equity of 4.8% beat ADC Therapeutics SA's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ALCAlcon AG55.78% $0.48 $27.3B ADCTADC Therapeutics SA91.95% -$0.30 $219.3M -
What do Analysts Say About ALC or ADCT?
Alcon AG has a consensus price target of $94.15, signalling upside risk potential of 16.63%. On the other hand ADC Therapeutics SA has an analysts' consensus of $8.00 which suggests that it could grow by 143.16%. Given that ADC Therapeutics SA has higher upside potential than Alcon AG, analysts believe ADC Therapeutics SA is more attractive than Alcon AG.
Company Buy Ratings Hold Ratings Sell Ratings ALCAlcon AG15 7 0 ADCTADC Therapeutics SA5 0 0 -
Is ALC or ADCT More Risky?
Alcon AG has a beta of 0.967, which suggesting that the stock is 3.321% less volatile than S&P 500. In comparison ADC Therapeutics SA has a beta of 1.887, suggesting its more volatile than the S&P 500 by 88.684%.
-
Which is a Better Dividend Stock ALC or ADCT?
Alcon AG has a quarterly dividend of $0.34 per share corresponding to a yield of 0.42%. ADC Therapeutics SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alcon AG pays 15.44% of its earnings as a dividend. ADC Therapeutics SA pays out -- of its earnings as a dividend. Alcon AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios ALC or ADCT?
Alcon AG quarterly revenues are $2.6B, which are larger than ADC Therapeutics SA quarterly revenues of $16.4M. Alcon AG's net income of $237M is higher than ADC Therapeutics SA's net income of -$41M. Notably, Alcon AG's price-to-earnings ratio is 38.36x while ADC Therapeutics SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alcon AG is 3.94x versus 5.06x for ADC Therapeutics SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ALCAlcon AG3.94x 38.36x $2.6B $237M ADCTADC Therapeutics SA5.06x -- $16.4M -$41M
-
Which has Higher Returns ALC or BSX?
Boston Scientific Corp. has a net margin of 9.07% compared to Alcon AG's net margin of 14.91%. Alcon AG's return on equity of 4.8% beat Boston Scientific Corp.'s return on equity of 12.46%.
Company Gross Margin Earnings Per Share Invested Capital ALCAlcon AG55.78% $0.48 $27.3B BSXBoston Scientific Corp.65.31% $0.50 $35.7B -
What do Analysts Say About ALC or BSX?
Alcon AG has a consensus price target of $94.15, signalling upside risk potential of 16.63%. On the other hand Boston Scientific Corp. has an analysts' consensus of $126.48 which suggests that it could grow by 29.7%. Given that Boston Scientific Corp. has higher upside potential than Alcon AG, analysts believe Boston Scientific Corp. is more attractive than Alcon AG.
Company Buy Ratings Hold Ratings Sell Ratings ALCAlcon AG15 7 0 BSXBoston Scientific Corp.25 2 0 -
Is ALC or BSX More Risky?
Alcon AG has a beta of 0.967, which suggesting that the stock is 3.321% less volatile than S&P 500. In comparison Boston Scientific Corp. has a beta of 0.673, suggesting its less volatile than the S&P 500 by 32.691%.
-
Which is a Better Dividend Stock ALC or BSX?
Alcon AG has a quarterly dividend of $0.34 per share corresponding to a yield of 0.42%. Boston Scientific Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alcon AG pays 15.44% of its earnings as a dividend. Boston Scientific Corp. pays out -- of its earnings as a dividend. Alcon AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios ALC or BSX?
Alcon AG quarterly revenues are $2.6B, which are smaller than Boston Scientific Corp. quarterly revenues of $5.1B. Alcon AG's net income of $237M is lower than Boston Scientific Corp.'s net income of $755M. Notably, Alcon AG's price-to-earnings ratio is 38.36x while Boston Scientific Corp.'s PE ratio is 52.16x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alcon AG is 3.94x versus 7.52x for Boston Scientific Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ALCAlcon AG3.94x 38.36x $2.6B $237M BSXBoston Scientific Corp.7.52x 52.16x $5.1B $755M
-
Which has Higher Returns ALC or NVS?
Novartis AG has a net margin of 9.07% compared to Alcon AG's net margin of 28.26%. Alcon AG's return on equity of 4.8% beat Novartis AG's return on equity of 33.87%.
Company Gross Margin Earnings Per Share Invested Capital ALCAlcon AG55.78% $0.48 $27.3B NVSNovartis AG74.59% $2.02 $76.8B -
What do Analysts Say About ALC or NVS?
Alcon AG has a consensus price target of $94.15, signalling upside risk potential of 16.63%. On the other hand Novartis AG has an analysts' consensus of $134.88 which suggests that it could grow by 2.06%. Given that Alcon AG has higher upside potential than Novartis AG, analysts believe Alcon AG is more attractive than Novartis AG.
Company Buy Ratings Hold Ratings Sell Ratings ALCAlcon AG15 7 0 NVSNovartis AG1 6 2 -
Is ALC or NVS More Risky?
Alcon AG has a beta of 0.967, which suggesting that the stock is 3.321% less volatile than S&P 500. In comparison Novartis AG has a beta of 0.525, suggesting its less volatile than the S&P 500 by 47.542%.
-
Which is a Better Dividend Stock ALC or NVS?
Alcon AG has a quarterly dividend of $0.34 per share corresponding to a yield of 0.42%. Novartis AG offers a yield of 3.02% to investors and pays a quarterly dividend of $3.99 per share. Alcon AG pays 15.44% of its earnings as a dividend. Novartis AG pays out 55.39% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios ALC or NVS?
Alcon AG quarterly revenues are $2.6B, which are smaller than Novartis AG quarterly revenues of $13.9B. Alcon AG's net income of $237M is lower than Novartis AG's net income of $3.9B. Notably, Alcon AG's price-to-earnings ratio is 38.36x while Novartis AG's PE ratio is 18.02x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alcon AG is 3.94x versus 4.78x for Novartis AG. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ALCAlcon AG3.94x 38.36x $2.6B $237M NVSNovartis AG4.78x 18.02x $13.9B $3.9B
-
Which has Higher Returns ALC or SOLV?
Solventum Corp. has a net margin of 9.07% compared to Alcon AG's net margin of 60.4%. Alcon AG's return on equity of 4.8% beat Solventum Corp.'s return on equity of 42.2%.
Company Gross Margin Earnings Per Share Invested Capital ALCAlcon AG55.78% $0.48 $27.3B SOLVSolventum Corp.53.91% $7.22 $10.1B -
What do Analysts Say About ALC or SOLV?
Alcon AG has a consensus price target of $94.15, signalling upside risk potential of 16.63%. On the other hand Solventum Corp. has an analysts' consensus of $84.36 which suggests that it could fall by -1.25%. Given that Alcon AG has higher upside potential than Solventum Corp., analysts believe Alcon AG is more attractive than Solventum Corp..
Company Buy Ratings Hold Ratings Sell Ratings ALCAlcon AG15 7 0 SOLVSolventum Corp.3 7 1 -
Is ALC or SOLV More Risky?
Alcon AG has a beta of 0.967, which suggesting that the stock is 3.321% less volatile than S&P 500. In comparison Solventum Corp. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock ALC or SOLV?
Alcon AG has a quarterly dividend of $0.34 per share corresponding to a yield of 0.42%. Solventum Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alcon AG pays 15.44% of its earnings as a dividend. Solventum Corp. pays out -- of its earnings as a dividend. Alcon AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios ALC or SOLV?
Alcon AG quarterly revenues are $2.6B, which are larger than Solventum Corp. quarterly revenues of $2.1B. Alcon AG's net income of $237M is lower than Solventum Corp.'s net income of $1.3B. Notably, Alcon AG's price-to-earnings ratio is 38.36x while Solventum Corp.'s PE ratio is 9.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alcon AG is 3.94x versus 1.77x for Solventum Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ALCAlcon AG3.94x 38.36x $2.6B $237M SOLVSolventum Corp.1.77x 9.83x $2.1B $1.3B
-
Which has Higher Returns ALC or STAA?
STAAR Surgical Co. has a net margin of 9.07% compared to Alcon AG's net margin of 9.38%. Alcon AG's return on equity of 4.8% beat STAAR Surgical Co.'s return on equity of -25.83%.
Company Gross Margin Earnings Per Share Invested Capital ALCAlcon AG55.78% $0.48 $27.3B STAASTAAR Surgical Co.80.89% $0.18 $392.9M -
What do Analysts Say About ALC or STAA?
Alcon AG has a consensus price target of $94.15, signalling upside risk potential of 16.63%. On the other hand STAAR Surgical Co. has an analysts' consensus of $25.88 which suggests that it could grow by 1.95%. Given that Alcon AG has higher upside potential than STAAR Surgical Co., analysts believe Alcon AG is more attractive than STAAR Surgical Co..
Company Buy Ratings Hold Ratings Sell Ratings ALCAlcon AG15 7 0 STAASTAAR Surgical Co.1 10 0 -
Is ALC or STAA More Risky?
Alcon AG has a beta of 0.967, which suggesting that the stock is 3.321% less volatile than S&P 500. In comparison STAAR Surgical Co. has a beta of 1.008, suggesting its more volatile than the S&P 500 by 0.806%.
-
Which is a Better Dividend Stock ALC or STAA?
Alcon AG has a quarterly dividend of $0.34 per share corresponding to a yield of 0.42%. STAAR Surgical Co. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alcon AG pays 15.44% of its earnings as a dividend. STAAR Surgical Co. pays out -- of its earnings as a dividend. Alcon AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios ALC or STAA?
Alcon AG quarterly revenues are $2.6B, which are larger than STAAR Surgical Co. quarterly revenues of $94.7M. Alcon AG's net income of $237M is higher than STAAR Surgical Co.'s net income of $8.9M. Notably, Alcon AG's price-to-earnings ratio is 38.36x while STAAR Surgical Co.'s PE ratio is 49.73x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alcon AG is 3.94x versus 5.47x for STAAR Surgical Co.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ALCAlcon AG3.94x 38.36x $2.6B $237M STAASTAAR Surgical Co.5.47x 49.73x $94.7M $8.9M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Robinhood Win AI Investing?
Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…
Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
81
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Buy
56
SMX alert for Dec 6
SMX (Security Matters) Plc [SMX] is up 134.09% over the past day.
Buy
62
PRAX alert for Dec 6
Praxis Precision Medicines, Inc. [PRAX] is up 30.47% over the past day.
Sell
13
PSN alert for Dec 6
Parsons Corp. [PSN] is down 21.1% over the past day.
